What's new? Log in Free sign up

Denali Capital Acquisition (DECA)

Company Profile

Company profile

Ticker

DECA, DECAW

Exchange

CEO

Mr. Lei Huang

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

Power & Digital Infrastructure Acquisition Corp.

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

DECA stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Business combination disclosure

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

Quarterly report

19 Nov 24

Notice of late quarterly filing

Business combination disclosure

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

Registration of securities issued in business combination transactions

Business combination disclosure

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

Business combination disclosure

Latest ownership filings

View all

METEORA CAPITAL, LLC

GLAZER CAPITAL, LLC

METEORA CAPITAL, LLC

Polar Asset Management Partners Inc.

CALAMOS INVESTMENT TRUST/IL

Denali Capital Global Investments LLC

Change in insider ownership

Scilex Holding Co

Shaolin Capital Management LLC

Financial summary

Financial statements Chart DECA financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	14.29 k	14.29 k	14.29 k	14.29 k	14.29 k	14.29 k
Cash burn (monthly)	(no burn)	(no burn)	70.98 k	77.66 k	55.74 k	67.91 k
Cash used (since last report)	n/a	n/a	200.03 k	218.83 k	157.07 k	191.36 k
Cash remaining	n/a	n/a	-185.75 k	-204.55 k	-142.78 k	-177.07 k
Runway (months of cash)	n/a	n/a	-2.6	-2.6	-2.6	-2.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

DECA institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	24	7	+242.9%
Opened positions	19	3	+533.3%
Closed positions	2	2	–
Increased positions	1	1	–
Reduced positions	1	0	NEW

13F shares	Current	Prev Q	Change
Total value	5.37 bn	4.01 bn	+33.8%
Total shares	9.06 mm	4.70 mm	+92.8%
Total puts	0.00	0.00
Total calls	470.00 k	0.00	NEW
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Denali Capital Global Investments	2.44 mm	$0.00	0.0%
Polar Asset Management Partners	1.40 mm	$28.00 mm	NEW
MFG Mizuho Financial	493.67 k	$0.00	0.0%
Boothbay Fund Management	470.00 k	$5.26 bn	NEW
Shaolin Capital Management	443.05 k	$8.86 mm	NEW
Saba Capital Management	410.00 k	$6.64 mm	NEW
Cubist Systematic Strategies	393.42 k	$7.87 mm	NEW
Hudson Bay Capital Management	376.82 k	$7.91 mm	NEW
Calamos Advisors	350.00 k	$7.35 mm	-50.0%
Cowen And	323.48 k	$6.47 mm	+65.3%

Largest transactions	Shares	Bought/sold	Change
Polar Asset Management Partners	1.40 mm	+1.40 mm	NEW
Context Capital Management	0.00	-605.00 k	EXIT
Boothbay Fund Management	470.00 k	+470.00 k	NEW
Shaolin Capital Management	443.05 k	+443.05 k	NEW
Saba Capital Management	410.00 k	+410.00 k	NEW
Cubist Systematic Strategies	393.42 k	+393.42 k	NEW
Hudson Bay Capital Management	376.82 k	+376.82 k	NEW
Calamos Advisors	350.00 k	-350.00 k	-50.0%
Taconic Capital Advisors	257.50 k	+257.50 k	NEW
D. E. Shaw & Co.	225.00 k	+225.00 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

DECA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
30 Aug 24	Jiandong Xu	Class B Ordinary Shares Class B Ordinary Shares	Sell	Dispose S	Yes	No	0	500,000	0.00	1,432,500
30 Aug 24	Denali Capital Global Investments	Class B Ordinary Shares Class B Ordinary Shares	Sell	Dispose S	No	No	0	500,000	0.00	1,432,500

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Scilex Explores Strategic Options, Analyst Initiates On Blockbuster Potential For Sciatica Pain Candidate

Alliance Global Partners has initiated coverage on Scilex Holding Company. The company explores strategic options for its subsidiary, Scilex Pharma, including potential spinoffs and dividend distributions, while anticipating significant sales from its pain treatment candidate, SEMDEXA.

Semnur Eyes Potential $2.5B Acquisition of SP-102 as Business Combination with Denali Nears

Semnur is currently in discussions regarding strategic regional and/or worldwide collaborations and potential outright acquisition of SP-102. Any such transactions may have the potential to provide value in excess of

Press releases

From Benzinga Pro

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

NEW YORK, NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali

As previously announced, Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC")) entered into an agreement and plan of

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 (the "Record Date") for the dividend of Scilex preferred stock to Scilex's stockholders and certain other securityholders of

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.